Loading...
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
Sternberg, C Hawkins, Robert E Wagstaff, J Salman, P Mardiak, J Barrios, C Zarba, J Gladkov, O Lee, E Szczylik, C
Sternberg, C
Hawkins, Robert E
Wagstaff, J
Salman, P
Mardiak, J
Barrios, C
Zarba, J
Gladkov, O
Lee, E
Szczylik, C
Citations
Altmetric:
Abstract
In this randomised phase III study (VEG105192; NCT00334282), pazopanib previously demonstrated statistically and clinically meaningful improvement of progression-free survival versus placebo in patients with advanced/metastatic renal cell carcinoma (mRCC). Final overall survival (OS) and updated safety results are now reported.
Description
Date
2013-04
Publisher
Collections
Keywords
Type
Article
Citation
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. 2013, 49 (6):1287-96 Eur J Cancer